| Coronavirus Antivirals |
|
| Cat. No. |
Product |
Activity |
| 4274 |
AP 24534 |
Identified as targeting human proteins in the SARS-CoV-2
interactome; potent multi-kinase and pan-Bcr-Abl inhibitor |
| 7283 |
Apilimod
dimesylate |
Inhibits cellular entry by SARS-CoV-2, MERS-CoV and MHV S
pseudovirions; potent and selective PIKfyve inhibitor |
| 7235 |
Arbidol |
Inhibits replication of SARS-CoV-2 in vitro; broad spectrum
antiviral |
| 4600 |
Auranofin |
Inhibits SARS-CoV-2 infection in vitro |
| 3771 |
Azithromycin |
Predicted to disrupt binding of SARS-CoV-2 spike protein to ACE2 |
| 7222 |
Baricitinib |
In silico modelling predicts inhibition of SARS-CoV-2 cell
entry; highly potent JAK inhibitor |
| 3193 |
Camostat
mesylate |
Inhibits entry of SARS-Cov-2 into lung cells; TMPRSS2 inhibitor |
| 4109 |
Chloroquine
diphosphate |
Inhibits SARS-CoV-2 infection in vitro |
| 6357 |
Ciclesonide |
Inhibits replication of SARS-CoV-2 in vitro; glucocorticoid |
| 0460 |
Cinanserin
hydrochloride |
Inhibits replication of SARS-CoV; Mpro inhibitor and 5-HT2 antagonist |
| 0970 |
Cycloheximide |
Exhibits anti-MERS-CoV activity in vitro; protein synthesis
inhibitor |
| 1101 |
Cyclosporin
A |
Inhibits coronavirus replication; cyclophilin inhibitor |
| 7223 |
Dabrafenib
mesylate |
Targets human proteins in the SARS-CoV-2 interactome; potent and
selective B-Raf, CDK16 and NEK9 inhibitor |
| 1467 |
Daunorubicin
hydrochloride |
Identified as targeting human proteins in the SARS-CoV-2
interactome; DNA topoisomerase II inhibitor |
| 4583 |
Digoxin |
Exhibits anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor |
| 7336 |
Dinaciclib |
Exhibits antiviral activity against SARS-CoV-2 in vitro;
potent and selective inhibitor of CDK2, CDK5, CDK1 and CDK9 |
| 3807 |
Disulfiram |
SARS-CoV-2 Mpro inhibitor;
also reversibly stimulates SERCA Ca2+-ATPase |
| 4545 |
E 64d |
Inhibts entry of SARS-CoV-2 into lung cells in combination
with Camostat (Cat. No. 3193); cathepsin inhibitor |
| 5245 |
Ebselen |
Inhibits SARS-CoV-2 Mpro in vitro; glutathione peroxidase mimic |
| 6986 |
EG
00229 trifluoroacetate |
Inhibits binding of cleaved spike protein of SARS-CoV-2 to
neuropilin 1 (NRP1); neuropilin 1 antagonist |
| 7231 |
EIDD 1931 |
Inhibits MERS-CoV and SARS-CoV-2 replication in vitro;
viral RNA-dependent RNA polymerase (RdRP) inhibitor |
| 7225 |
Favipiravir |
Reduces infection rate of SARS-CoV-2 in vitro; viral RNA
polymerase inhibitor |
| 3631 |
FK 506 |
Identified as targeting human proteins in the SARS-CoV-2
interactome; potent calcineurin inhibitor |
| 7229 |
Galidesivir
dihydrochloride |
Broad spectrum antiviral nucleotide; inhibits coronavirus
replication in vitro |
| 3259 |
Gemcitabine
hydrochloride |
Inhibits replication of coronaviruses; DNA synthesis inhibitor |
| 7280 |
GRL 0617 |
Coronavirus PLpro inhibitor |
| 7227 |
GS 441524 |
Displays antiviral activity against MERS-CoV, SARS-CoV and
SARS-CoV-2; viral RNA-dependent RNA polymerase (RdRp) inhibitor; active
metabolite of Remdesivir (Cat. No. 7226) |
| 1416 |
Homoharringtonine |
Inhibits SARS-CoV-2 infection in vitro; inhibits protein
synthesis |
| 5648 |
Hydroxychloroquine
sulfate |
Inhibits SARS-CoV-2 viral infection in vitro |
| 5906 |
Imatinib
mesylate |
Inhibits replication of SARS-CoV and MERS-CoV in vitro;
potent and selective v-Abl tyrosine kinase inhibitor |
| 1708 |
Indomethacin |
Identified as targeting human proteins in the SARS-CoV-2
interactome |
| 1260 |
Ivermectin |
Inhibits replication of SARS-Cov-2 in vitro; antiparasitic
and antiviral |
| 2959 |
Lercanidipine
hydrochloride |
Exhibits anti-MERS-CoV activity in vitro; CaV1.x blocker |
| 3765 |
Linezolid |
Identified as targeting human proteins in the SARS-CoV-2
interactome; antibiotic |
| 0840 |
Loperamide
hydrochloride |
Inhibits replication of coronaviruses in vitro;
peripherally acting μ opioid agonist and Ca2+ channel blocker |
| 7052 |
Lopinavir |
Inhibits SARS-CoV-2 replication in vitro; highly potent and
selective HIV-1 protease inhibitor |
| 6819 |
Mefloquine
hydrochloride |
Exhibits antiviral activities against SARS-CoV-2; also Cx36 and
Cx50 gap channel blocker |
| 2864 |
Metformin
hydrochloride |
Identified as targeting human proteins in the SARS-CoV-2
interactome; antidiabetic |
| 7228 |
MPro 13b |
Coronavirus Mpro inhibitor |
| 7230 |
MPro N3 |
Coronavirus Mpro inhibitor |
| 3081 |
Nafamostat
mesylate |
Inhibits SARS-CoV-2 infection in vitro; serine protease
inhibitor |
| 3766 |
Nelfinavir
mesylate |
Exhibits anti-MERS-CoV activity in vitro; potent HIV-1
protease inhibitor |
| 4079 |
Niclosamide |
Inhibits SARS-CoV-2 spike protein induced syncytia formation and
viral replication in vitro; also STAT3 inhibitor |
| 7234 |
Nitazoxanide |
Inhibits SARS-CoV-2 infection in vitro; Pyruvate
flavodoxin/ferredoxin oxidoreductase (PFOR) inhibitor |
| 2583 |
Omeprazole |
Enhances anti-SARS-CoV-2 activity of serine protease inhibitors |
| 1076 |
Ouabain |
Exhibits anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor |
| 7357 |
PLpro
inhibitor 6 |
SARS-CoV and SARS-CoV-2 PLpro inhibitor |
| 1125 |
Quercetin |
Inhibits SARS-CoV Mpro; also non-selective PI 3-kinase inhibitor |
| 1292 |
Rapamycin |
Inhibits MERS-CoV infection; mTOR inhibitor and
immunosuppressant |
| 7226 |
Remdesivir |
Displays antiviral activity against MERS-CoV, SARS-CoV and
SARS-CoV-2; viral RNA-dependent RNA polymerase (RdRp) inhibitor |
| 4501 |
Ribavirin |
Inhibits cytopathic effect of SARS-CoV in vitro; guanosine
analog and IMPDH inhibitor |
| 5856 |
Ritonavir |
Improves outcome in an animal model of MERS-CoV infection; HIV
protease inhibitor |
| 7064 |
Ruxolitinib |
Targets human proteins in the SARS-CoV-2 interactome; potent and
selective JAK1/JAK2 inhibitor |
| 7191 |
Santacruzamate
A |
Identified as targeting human host proteins that interact with
SARS-CoV-2 |
| 7189 |
Saracatinib |
Inhibits MERS-CoV, other coronaviruses and dengue virus |
| 7192 |
SMIP 004 |
S-phase kinase-associated protein 2 (SKP2) inhibitor; inhibits
MERS-CoV replication and induces autophagy in infected cells |
| 1138 |
Thapsigargin |
Inhibits SARS-CoV-2 infection in vitro; SERCA inhibitor |
| 2815 |
Valproic
acid, sodium salt |
Identified as targeting human proteins in the SARS-CoV-2
interactome; HDAC inhibitor |
| 0654 |
Verapamil
hydrochloride |
Targets human proteins in the SARS-CoV-2 interactome; CaV1.x blocker |
|
|
|
| ACE2 |
|
|
| Cat. No. |
Product |
Activity |
| 7199 |
(±)-Eriodictyol |
Predicted by modeling studies to bind ACE2; potent TRPV1
antagonist and antioxidant |
| 1563 |
Angiotensin
I (human, mouse, rat) |
Potent endogenous vasoconstrictor peptide; substrate for ACE and
ACE2 |
| 1158 |
Angiotensin
II |
Potent endogenous vasoconstrictor peptide; substrate for ACE2 |
| 3345 |
MLN 4760 |
Potent and selective angiotensin-converting enzyme 2 (ACE2)
inhibitor |
| 7233 |
SBP1 |
ACE2 derived peptide; binds SARS-CoV-2 spike protein receptor
binding domain |
| 7232 |
SBP1-FITC |
Fluorescent ACE2-derived peptide; binds receptor binding domain
of SARS-CoV-2 spike protein |
| 7322 |
SP 10 |
Highly potent inhibitor of SARS-CoV Spike (S) protein and ACE2
interaction |
|
|
|
| Furin Inhibitor |
|
|
| Cat. No. |
Product Name |
Activity |
| 3501 |
Decanoyl-RVKR-CMK |
Furin inhibitor; blocks SARS-CoV-2 spike protein cleavage and
blocks viral cell entry |
| 4711 |
Hexa-D-arginine |
Furin inhibitor |
| 5253 |
SSM
3 trifluoroacetate |
Potent furin inhibitor |